Ascletis Pharma (HKG:1672) said it has dosed the first patients in its US clinical study for the combination of ASC47 and semaglutide for weight loss patients who do not have type 2 diabetes.
ASC47 is indicated for obese patients and adipose tissue or body fat, according to a Tuesday filing with the Hong Kong bourse.
The drug reduced body weight by about 57% and preserved muscles in diet-induced obese mouse models, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.